55 Corporate Drive
91 articles with Sanofi
Interim Data Evaluating Elocta® for Immune Tolerance Induction in People With Inhibitors and Severe Haemophilia A Shared at ISTH 2019
Interim results from verITI-8, an ongoing prospective, phase 4 study evaluating the efficacy of Elocta®, for first-time Immune Tolerance Induction for people with severe haemophilia A with inhibitors were presented.
The increase in smoking and the consumption of tobacco products have resulted in increased incidences of laryngeal cancer.
BIOCORP Enters Exclusive Negotiations With SANOFI to Use Their MallyaTM Connected Device With Sanofi’s Integrated Diabetes Care Platform
BIOCORP announces that they have entered into an exclusive negotiation with SANOFI, aimed at introducing their Mallya connected device into SANOFI's integrated diabetes care platform.
Libtayo is the only treatment approved in the EU for adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent®, recommending to extend its approval in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.
Companies share robust oncology data at annual ASCO meeting.
Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months
Sanofi's oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering against a renewed strategy to address difficult-to-treat and difficult-to-eradicate cancers, including certain types of multiple myeloma, skin cancer, breast cancer, and lung cancer.
Individualised Extended Half-life Factor Replacement Therapy Controls Haemostasis in Orthopaedic Surgery
Sobi™ and Sanofi will present data demonstrating that Elocta® and Alprolix® can provide perioperative haemostatic control across a wide spectrum of major and minor surgeries in subjects of all ages with severe haemophilia A and B respectively.
Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO)
Relapsing MS Patients Who Received Aubagio® (teriflunomide) Experienced a Reduced Risk of Relapse Regardless of Prior Treatment Status in a Post-Hoc Analysis
These results will be presented this week during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.
FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
First-quarter sales(2) growth driven by Specialty Care, Vaccines and strong contribution from Emerging Markets
Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program
The companies are currently advancing programs in oncology and autoimmune disease.
Alnylam to Advance Selected Investigational Asset in an Undisclosed Rare Genetic Disease Through the End of IND-Enabling Studies
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
Conference call and webcast scheduled for 8:00 a.m. Eastern Time
Multinational Biotech company quickly achieves data security and compliance objectives with Rubrik Cloud Data Management